Trials / Withdrawn
WithdrawnNCT04320290
HCV + to HCV - Kidney Transplant
Hepatitis C Viral Kidneys Used for Non-Viremic Recipients
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Massachusetts General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single center study characterizing the experience of administration of 8 weeks of pan-genotypic DAA therapy in kidney transplantation to prevent the transmission of hepatitis C virus infection from an HCV-positive donor kidney to an HCV-negative recipient.
Detailed description
The goal of this study is to determine if 8 weeks of preemptive and sustained administration of pan-genotypic DAA therapy after kidney transplant prevents the transmission of hepatitis C virus (HCV) infection from an HCV-positive donor kidney to an HCV-naive recipient.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Direct Acting Antivirals | 8 weeks of DAA treatment |
Timeline
- Start date
- 2020-05-21
- Primary completion
- 2020-06-16
- Completion
- 2020-06-16
- First posted
- 2020-03-24
- Last updated
- 2022-08-31
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04320290. Inclusion in this directory is not an endorsement.